The use of antisense oligonucleotides to target specific mRNA sequences represents a promising therapeutic strategy for neurological disorders. Recent advances in antisense technology enclose the development of phosphorodiamidate morpholino oligomers (MO), which is one of the best candidates for molecular therapies due to MOâs excellent pharmacological profile. Nevertheless, the route of administration of antisense compounds represents a critical issue in the neurological field. Particularly, as regards motor neuron diseases, intracerebroventricular (ICV) injection is undoubtedly the most efficient procedure to directly deliver therapeutic molecules in the central nervous system (CNS). Indeed, we recently demonstrated the outstanding efficacy of the MO antisense approach by its direct administration to CNS of the transgenic mouse models of Spinal Muscular Atrophy (SMA) and Amyotrophic Lateral Sclerosis (ALS). Here, we describe methods to perform the ICV delivery of MO in neonatal SMA mice and in adult ALS mice.
Intracerebroventricular delivery in mice for motor neuron diseases / M. Nizzardo, M. Rizzuti (METHODS IN MOLECULAR BIOLOGY). - In: Morpholino Oligomers : Methods and Protocols / [a cura di] H.M. Moulton, J.D. Moulton. - [s.l] : Humana Press Inc., 2017. - ISBN 9781493968152. - pp. 229-239 [10.1007/978-1-4939-6817-6_19]
Intracerebroventricular delivery in mice for motor neuron diseases
M. Nizzardo;M. Rizzuti
2017
Abstract
The use of antisense oligonucleotides to target specific mRNA sequences represents a promising therapeutic strategy for neurological disorders. Recent advances in antisense technology enclose the development of phosphorodiamidate morpholino oligomers (MO), which is one of the best candidates for molecular therapies due to MOâs excellent pharmacological profile. Nevertheless, the route of administration of antisense compounds represents a critical issue in the neurological field. Particularly, as regards motor neuron diseases, intracerebroventricular (ICV) injection is undoubtedly the most efficient procedure to directly deliver therapeutic molecules in the central nervous system (CNS). Indeed, we recently demonstrated the outstanding efficacy of the MO antisense approach by its direct administration to CNS of the transgenic mouse models of Spinal Muscular Atrophy (SMA) and Amyotrophic Lateral Sclerosis (ALS). Here, we describe methods to perform the ICV delivery of MO in neonatal SMA mice and in adult ALS mice.File | Dimensione | Formato | |
---|---|---|---|
nizzardo chapter 1.pdf
accesso riservato
Tipologia:
Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione
247.95 kB
Formato
Adobe PDF
|
247.95 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.